About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 57 record(s)
Req # A-2023-00089
Aggregate amounts spent on legal fees billed by external counsel for work in respect of ATI complaints before the OIC and federal court, each year since 2018, broken down by year.Organization: Export Development Canada
September 2023
Req # A-2023-00097
Please provide a copy of the current version of each of the three guidelines documents - Anti-Money Laundering and Anti-Terrorist Financing Guideline - Sanctions Guideline - Anti-Bribery and Anti-Corruption GuidelineOrganization: Export Development Canada
September 2023
Req # A-2023-000313
The licensed indications for use for MicroTheurapeutic‘s Axium Embolization Coils on Medical Device License 63475 that Health Canada has on file for this license.Organization: Health Canada
September 2023
Req # A-2023-000713
A copy of all information released as part of Freedom of Information (FOI) request number A-2016-00717, completed by your office around October 1, 2016.Organization: Health Canada
September 2023
Req # A-2021-000663
Adverse Drug Reaction (ADR) for HYOSCINE BUTYLBROMIDE. Report number: E2B_03293753.Organization: Health Canada
September 2023
Req # A-2022-001661
Adverse Drug Reaction (ADR). Report number: E2B_05716216.Organization: Health Canada
September 2023
Req # A-2023-000352
Adverse Drug Reaction (ADR) for LANREOTIDE. Report number: E2B_05322380.Organization: Health Canada
September 2023
Req # A-2023-000381
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_03009425, E2B_01335934, E2B_02096585, E2B_01892634, E2B_02393844, E2B_02387551, E2B_02826826, E2B_02867073, E2B_02455143, E2B_03044908.Organization: Health Canada
September 2023
Req # A-2023-000416
Adverse Drug Reaction (ADR). Report number: 000630138.Organization: Health Canada
September 2023
Req # A-2023-000468
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103496-815, Investing in Canada Plan.Organization: Health Canada
September 2023